Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04287829
Title Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (PEMMELA)
Acronym PEMMELA
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The Netherlands Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD


No variant requirements are available.